Beijing SL Pharmaceutical Co Ltd - Asset Resilience Ratio
Beijing SL Pharmaceutical Co Ltd (002038) has an Asset Resilience Ratio of 8.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Beijing SL Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check 002038 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Beijing SL Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002038 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥512.01 Million | 8.77% |
| Total Liquid Assets | CN¥512.01 Million | 8.77% |
Asset Resilience Insights
- Limited Liquidity: Beijing SL Pharmaceutical Co Ltd maintains only 8.77% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beijing SL Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing SL Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 28.06% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Beijing SL Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Beijing SL Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.22% | CN¥498.95 Million ≈ $73.01 Million |
CN¥6.07 Billion ≈ $888.54 Million |
+0.17pp |
| 2024-12-31 | 8.04% | CN¥480.86 Million ≈ $70.36 Million |
CN¥5.98 Billion ≈ $874.92 Million |
-15.04pp |
| 2023-12-31 | 23.08% | CN¥1.45 Billion ≈ $212.06 Million |
CN¥6.28 Billion ≈ $918.63 Million |
+8.48pp |
| 2022-12-31 | 14.61% | CN¥858.27 Million ≈ $125.59 Million |
CN¥5.88 Billion ≈ $859.82 Million |
+11.79pp |
| 2021-12-31 | 2.82% | CN¥162.36 Million ≈ $23.76 Million |
CN¥5.76 Billion ≈ $842.94 Million |
-0.40pp |
| 2020-12-31 | 3.22% | CN¥173.81 Million ≈ $25.43 Million |
CN¥5.39 Billion ≈ $789.43 Million |
+0.53pp |
| 2019-12-31 | 2.69% | CN¥140.45 Million ≈ $20.55 Million |
CN¥5.22 Billion ≈ $764.58 Million |
+2.09pp |
| 2018-12-31 | 0.59% | CN¥29.65 Million ≈ $4.34 Million |
CN¥4.99 Billion ≈ $729.94 Million |
-0.94pp |
| 2017-12-31 | 1.53% | CN¥70.31 Million ≈ $10.29 Million |
CN¥4.59 Billion ≈ $670.94 Million |
+0.64pp |
| 2016-12-31 | 0.89% | CN¥36.48 Million ≈ $5.34 Million |
CN¥4.08 Billion ≈ $597.22 Million |
-0.14pp |
| 2015-12-31 | 1.03% | CN¥38.73 Million ≈ $5.67 Million |
CN¥3.76 Billion ≈ $550.44 Million |
+0.74pp |
| 2014-12-31 | 0.29% | CN¥9.47 Million ≈ $1.39 Million |
CN¥3.32 Billion ≈ $485.68 Million |
+0.05pp |
| 2013-12-31 | 0.23% | CN¥6.35 Million ≈ $929.58K |
CN¥2.71 Billion ≈ $396.87 Million |
-0.17pp |
| 2012-12-31 | 0.40% | CN¥8.91 Million ≈ $1.30 Million |
CN¥2.22 Billion ≈ $324.37 Million |
-0.10pp |
| 2011-12-31 | 0.51% | CN¥8.78 Million ≈ $1.29 Million |
CN¥1.74 Billion ≈ $254.05 Million |
-0.42pp |
| 2010-12-31 | 0.93% | CN¥11.57 Million ≈ $1.69 Million |
CN¥1.25 Billion ≈ $182.71 Million |
-1.22pp |
| 2009-12-31 | 2.14% | CN¥21.86 Million ≈ $3.20 Million |
CN¥1.02 Billion ≈ $149.23 Million |
+0.59pp |
| 2008-12-31 | 1.55% | CN¥12.22 Million ≈ $1.79 Million |
CN¥788.52 Million ≈ $115.38 Million |
-3.74pp |
| 2007-12-31 | 5.29% | CN¥31.05 Million ≈ $4.54 Million |
CN¥586.63 Million ≈ $85.84 Million |
+1.66pp |
| 2005-12-31 | 3.64% | CN¥14.76 Million ≈ $2.16 Million |
CN¥405.91 Million ≈ $59.40 Million |
-5.59pp |
| 2003-12-31 | 9.22% | CN¥14.00 Million ≈ $2.05 Million |
CN¥151.83 Million ≈ $22.22 Million |
-- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more